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Objective: We report a case of an adrenal collision tumor composed of a small cell lung carcinoma metastasis and
a benign adrenal adenoma identified preoperatively on FDG-PET, CT and MRI and confirmed pathologically.
Methods: The patient’s history, preoperative imaging characteristics, postoperative course, and histopathology are
described. A review of the literature addressing adrenal collision tumors is provided.
Results: A 47-year-old female was found to have a left upper lobe lung mass and an adrenal lesion on imaging.
FDG-PET, CT and MRI of the adrenal suggested a metastatic lesion adjacent to an adrenal adenoma. CT-guided
biopsy of the adrenal gland was consistent with a small cell lung cancer metastasis. The patient underwent systemic
chemotherapy and had complete resolution of the left upper lobe mass. Post-treatment FDG-PET demonstrated a
persistently enlarged adrenal gland with decreased but persistent FDG uptake. The patient underwent adrenalectomy
and pathologic examination demonstrated a small cell lung cancer/adenoma collision tumor.
Conclusions: This case and a review of the literature demonstrate that FDG, CT and MR imaging can all characterize
the separate components of collision tumors within the adrenal gland.
Keywords: Collision tumor, Small cell lung cancer, Adrenal adenoma, Fluorodeoxyglucose positron emission
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Composite tumors are those that have two different
histologic types intermixed, whereas collision tumors are
those in which two tumors abut each other or are in
close proximity [1]. Collision tumors have been reported
in nearly every organ in the body. They may be composed
of two primary tumors from the same organ, or a primary
tumor and a metastasis. The close approximation of
two malignancies can create diagnostic and therapeutic
dilemmas. If a mixed benign and malignant collision
tumor is biopsied and only the benign component
identified, sub-optimal treatment may be delivered.
Here we report an unusual case of a patient noted to have
two left adrenal lesions on imaging, which were correctly
characterized radiologically as a metastasis adjacent to a* Correspondence: untchb@mskcc.org
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reproduction in any medium, provided the orbenign adrenal adenoma. This was confirmed by fine
needle aspirate cytology and pathology after adrenalectomy.
To our knowledge this is the first reported case of a
small-cell lung carcinoma and adrenal adenoma collision
tumor.Case presentation
A 47-year-old woman developed cough and hoarseness
that persisted after a course of antibiotics. A computed
tomography (CT) scan of the chest revealed a 6.0-cm
mass in the left upper lobe of the lung and bulky hilar
adenopathy. In the left adrenal, two lesions were identified
on non-contrast-enhanced images: a low-attenuation
2.9 × 3.1-cm lesion suggestive of a lipid-rich adenoma, and
a higher attenuation 1.2 × 1.4-cm nodule suspicious
for metastatic disease (Figure 1A). Fluorodeoxyglucose
positron emission tomography (FDG-PET) confirmed that
the low attenuation lesion of 5 Hounsfield units was not
hypermetabolic. The standardized uptake value basedtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Figure 1 Pretreatment imaging of an adrenal collision tumor. (A) Non-contrast axial computed tomography scan (CT) demonstrating two
distinct lesions in the left adrenal gland: a low attenuation 2.9 × 3.1-cm lesion as well as a higher attenuation 1.2 × 1.4-cm nodule, suspicious for
metastatic disease. (B) Fused CT/fluorodeoxyglucose (FDG) positron emission tomography scan demonstrates an FDG avid lesion in the high
attenuation component (standardized uptake value (SUVmax) 7) and no significant uptake in the low attenuation component. (C) Opposed-phase
axial magnetic resonance imaging shows loss of signal intensity in the majority of the left adrenal mass, consistent with a lipid-rich adrenal adenoma,
largely surrounding a 1.2-cm mass within the lateral portion of the adrenal gland that did not lose signal intensity, suggestive of metastatic disease.
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an adenoma. The smaller, higher attenuation lesion
(31 Hounsfield units) within the adrenal was hypermeta-
bolic (SUVmax 7) consistent with metastatic disease
(Figure 1B). At chemical-shift magnetic resonance imaging
(MRI), two distinctly different components were demon-
strated, also suggestive of a collision tumor (Figure 1C). A
percutaneous CT-guided biopsy of the adrenal tumor
revealed malignant cells consistent with small-cell lung
cancer. After treatment with six courses of etoposide and
cisplatin, her CT scan showed a marked decrease in the
size of the lung tumor as well as near complete resolution
of the associated lymphadenopathy. However, the left
adrenal remained persistently enlarged on CT, despite a
decrease in FDG avidity on PET imaging (SUVmax
decreased from 7.0 to 2.7). Given the patient’s age and re-
sponse to chemotherapy, adrenalectomy was recommendedNuclear TTF-1
Small Cell Ca       Adenoma         
Figure 2 Immunohistochemistry of resected collision tumor. Nuclear t
and cytoplasmic chromogranin staining (right) were positive in the small cto determine the presence of persistent disease after
chemotherapy, and possibly to render the patient free of
metastases. Lung resection was not thought to be beneficial
because of the tumor response noted on imaging. The
patient underwent an uncomplicated laparoscopic left
adrenalectomy. Pathologic examination of the adrenal
revealed a small-cell lung carcinoma metastasis adjacent
to an adrenal adenoma. Nuclear thyroid transcription
factor-1 (TTF-1) and cytoplasmic chromogranin immuno-
histochemical staining were positive in the small-cell
carcinoma component, but not in the adrenal adenoma
(Figure 2). Postoperatively the patient underwent a further
three months of chemotherapy.
The patient remained free of disease for 1 year, but was
then found to have pancreatic metastases. She died
4 months later, approximately two years after her original
diagnosis.Cytoplasmic Chromogranin
Small Cell Ca           Adenoma
hyroid transcription factor-1 (TTF-1) immunohistochemical staining (left)
ell carcinoma component, but not in the adrenal adenoma.
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The reason why collision tumors develop is unclear.
Malignancies have been found to promote local and dis-
tant sites of disease, and it is plausible that these same fac-
tors could facilitate the growth of second primary tumors.
The initial tumor may create a milieu that makes it easier
for a second tumor to grow [2,3]; in vitro and clinical evi-
dence suggests that peri-tumoral tissue can facilitate the
growth of tumor cells in and around the primary tumor
via paracrine signaling [4,5]. Primary tumors are capable
of secreting circulating growth factors that can facilitate
metastatic spread and subsequent metastatic tumor
growth [6]. Also playing a role may be bone marrow-
derived cells which, when recruited to tumor sites, can fa-
cilitate growth of the primary tumor and metastases [7].
Collision tumors are rare in the adrenal gland at
imaging, occurring in 2 out of 104 patients MRI in a study
by Schwartz et al. [2]. Case reports of biopsy-proven
adrenal collision tumors in the literature are summarized
in Table 1. In all cases, primary adrenal tumors were one
component of the collision tumor [2,8-13]. In 9 of 11
patients, the second tumor was a metastasis. Identification
of the tumors by imaging was successful in all but one
case [8]. This case was a large heterogeneous tumor that
was composed of a rectal cancer metastasis and an adrenal
carcinosarcoma. Otherwise, CT and MRI were able to
successfully demonstrate that two different tumor
types were present in the same adrenal gland. In this case
the successful imaging identification of a collision tumor
led to appropriate biopsy of a metastasis and subsequent
systemic therapy.
Various radiologic techniques are available for char-
acterization of adrenal masses discovered incidentally





Bertolini et al. [8] Adrenal carcinosarcoma Rectal cancer
Thorin-Savoure et al. [9] Adrenal adenoma Sigmoid cancer
Thorin-Savoure et al. [9] Adrenal adenoma Breast cancer
Hagspiel [10] Adrenal myelolipoma* Hodgkin’s lymphoma*
Blake et al. [11] Adrenal adenoma Spermatic cord
leiomyoscarcoma
Otal et al. [12] Adrenal adenoma Adrenal myelolipoma
Otal et al. [12] Adrenal adenoma Adrenal myelolipoma
Schwartz et al. [2] Adrenal adenoma Non-small cell lung canc
Schwartz et al. [2] Adrenal adenoma Breast cancer
Hoshi et al. [13] Adrenal adenoma* Non-small-cell lung canc
Untch et al.
(Current study)
Adrenal adenoma Small-cell lung cancer
*Histology confirmed at autopsy. CT, computed tomography; MRI, magnetic resonaApproximately 7 to 10% of such masses represent
adrenal adenomas, which can be identified on non-contrast
CT if their attenuation measures less than 10 Hounsfield
units, or by the more sensitive quantitative changes in
enhancement values obtained at baseline and at 15-minute
washout CT. Alternatively, chemical-shift imaging can
identify about 70% of adrenal adenomas as such, based on
their high lipid content. On opposed-phase images,
the signal intensities of the intermixed lipid and water
components present within an adenoma will cancel
each other, resulting in signal loss in those locations
relative to the in-phase images. At PET scanning, adrenal
adenomas generally show low FDG avidity. In retrospect,
the patient in this case report could have been managed
with a combined PET/CT alone as this also allows for
interval evaluation of the tumor metabolic activity after
systemic therapy.
The decision to pursue adrenalectomy for this patient
was based on the patient’s age, the excellent treatment
response, and the persistent adrenal lesion noted on CT
that had a discordant FDG-PET response compared to
the primary site of disease. Additionally, the literature
supports the possible benefit of resection of a solitary
site of hematogenous metastasis in non-small-cell lung
cancer [15]. The efficacy and safety of laproscopic adrenal-
ectomy has made metastasectomy a favored approach for
patients with isolated metastatic disease. The laparoscopic
approach is associated with shorter hospital stay, lower
blood loss and lower morbidity [16,17] This, combined
with the five-year survival data ranging from 24 to 31%,
depending on the tumor type, makes the treatment
approach reasonable in select patients [18,19].
In summary, we report the first case in the literature





CT/MRI One heterogeneous tumor 14 cm
CT Two components of different attenuation 3 cm
CT Two components of different attenuation 4.1 cm
CT Two components of different attenuation 1.2. cm
PET/CT Two components of different attenuation
and metabolic activity
2.5 cm
CT/MRI Two components of different attenuation
and signal intensity
NA
CT Two components of different attenuation NA
er MRI Two components of different signal intensity NA
MRI Two components of different signal intensity NA
er* CT Two components of different attenuation NA
CT/PET/MRI Two components of different attenuation,
signal intensity, and metabolic activity
2.5 cm
nce imaging; PET, positron emission tomography; NA – not available.
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onstrate that FDG-PET, CT and MRI can all distinguish
two separate components of collision tumors within the
adrenal gland and, in the case of adrenal adenoma,
provide a definitive diagnosis for that component. When a
satisfactory post-treatment evaluation of such lesions
is not possible with these imaging modalities, surgical
intervention in select patients should be considered.
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